Thera-SAbDab

GOLIMUMAB

>   Structural Summary
TherapeuticGolimumab
TargetTNFA
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK
100% seqID Fv Structure5yoy [Fvs: GD, HE, IF, PM, QN, RO]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2004
INN Year Recommended2005
Companies InvolvedCentocor, Centocor Ortho Biotech, Janssen Biotech, Merck & Co, Mitsubishi Tanabe Pharma Corporation, Medarex
Conditions ApprovedAnkylosing spondylitis, Juvenile rheumatoid arthritis, Non-radiographic axial spondyloarthritis, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis
Conditions ActiveHearing disorders, Type 1 diabetes mellitus
Conditions DiscontinuedAsthma, Cardiovascular disorders, Sarcoidosis, Uveitis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]